Results 241 to 250 of about 181,112 (317)
P02.272 Follow up study of atypical antipsychotics for patients with psychiatric disorders and intellectual disability [PDF]
M. Vanstaelen+3 more
openalex +1 more source
ABSTRACT Introduction Management of hepatic encephalopathy relies on the identification and control of precipitating factors (PF). The prognostic value of a PF is unknown, which we aimed to explore. Patients and Methods Single‐center retrospective study of cirrhotic patients included in a prospective cohort admitted to an intensive care unit (ICU ...
Marika Rudler+7 more
wiley +1 more source
Editorial: Drug repurposing for cancer treatment: current and future directions. [PDF]
Lampros M+4 more
europepmc +1 more source
Weight Gain and Antipsychotic Medications
Ralph Aquila, Marianne Emanuel
openalex +2 more sources
Probing Cortical Sites of Antipsychotic Drug Action within vivoReceptor Imaging [PDF]
Philip Shaw, Lyn S. Pilowsky
openalex +1 more source
ABSTRACT Background Etrasimod is an oral, once‐daily (q.d.), selective sphingosine 1‐phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). Unlike the S1P receptor modulator ozanimod, etrasimod does not have a molecular structure to inhibit monoamine oxidase (MAO).
Anita Afzali+12 more
wiley +1 more source
Paliperidone-induced neuroleptic malignant syndrome: A case report. [PDF]
Unal GA.
europepmc +1 more source
Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis [PDF]
John Geddes+3 more
openalex +1 more source
Clozapine as a Model for Antipsychotic Development
F. Nucifora+3 more
semanticscholar +1 more source